Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher Syndrome

NCT04355689 is registered in ClinicalTrials.gov with Nacuity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04355689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04355689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher Syndrome
Lead sponsor
Nacuity Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 3, 2020
Completion date
April 22, 2026
Enrollment
49 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

usher syndromes